A Randomized, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study of a Fixed-Dose Combination of Phentermine/Topiramate in Adolescents with Obesity.
The purpose of this study was to assess the pharmacokinetics and pharmacodynamics of VI-0521, a fixed-dose combination of immediate-release phentermine (PHEN) and extended-release (ER) topiramate (TPM) in adolescents 12 to 17 years of age with obesity. Weight loss and adverse events using this drug combination are also reported. This was a multicenter, randomized, double-blind, parallel-design, placebo-controlled study in adolescents with obesity. 42 adolescents were randomly assigned in a 1:1:1 ratio to placebo, mid-dose (PHEN/TPM 7.5 mg/46 mg), or top-dose (PHEN/TPM 15 mg/92 mg) of VI-0521. A total of 26 adolescents were included in the PK analysis (14 from the mid-dose group and 12 from the top-dose group). At Day 56, arithmetic means of terminal elimination half-life (T½ ), apparent clearance (CL/F) and apparent volume of distribution (Vc/F) were consistent across dose levels for both PHEN and TPM. Arithmetic means of CL/F and Vc/F for PHEN and TPM administered as a combination in adolescents with obesity were within 10%-30% of those previously assessed in adults with obesity enrolled in Phase II and III studies. A higher proportion of adolescents in both the mid- and top-dose groups (13.3% and 50.0%, respectively) compared with placebo (0.0%) reached ≥5% weight loss at Day 56. The least square (LS) mean change in systolic blood pressure from baseline to Week 56 was -5.2 mmHg for the placebo group, -2.5 mmHg for the mid-dose group, and -5.5 mmHg for the top-dose group. The LS mean change in diastolic blood pressure (DBP) from baseline to Day 56 was -2.4 mmHg for the placebo group, +3.8 mmHg for the mid-dose group, and +2.0 mmHg for the top-dose group. Participants in the top-dose group had increases in heart rate from baseline of 4.1 bpm while participants in the mid-dose group experienced a mean decrease in heart rate of 4.5 bpm at Day 56. Both PHEN/TPM dose combinations were safe and well tolerated. Treatment of adolescents with obesity using a fixed-dose combination of phentermine/topiramate for 8 weeks resulted in exposure to PHEN and TPM that was comparable to that observed in adults, statistically significant weight loss, and a tolerable safety profile. These data indicate that both mid- and top-doses are appropriate for longer term safety and efficacy studies in adolescents. This article is protected by copyright. All rights reserved.